How big is the gene therapy starting materials market?

The market size of gene therapy starting materials is estimated at USD 3.01 billion in 2027.

What is the expected industry size of gene therapy starting materials by 2036?

Gene Therapy Starting Materials Market size was around USD 2.57 billion in 2026 and is slated to grow at a 19.97% CAGR from 2027 to 2036, exceeding USD 15.87 billion by 2036.

How are advances in gene therapy technologies reshaping demand for starting materials?

Progress in viral vectors and CRISPR-based solutions is increasing requirements for specialized materials supporting vector production, gene editing, cell processing, and other critical stages as therapeutic development becomes more sophisticated.

Why is manufacturing infrastructure becoming important for gene therapy starting materials?

Expanding contract manufacturing and supply chain capabilities are improving access to specialized processing, quality control, and scalable production, helping developers address manufacturing complexity as programs advance toward clinical and commercial stages.

Why do clinical therapeutics account for the largest share of gene therapy starting materials demand?

Clinical therapeutics held a 50.95% market share in 2026, driven by demand for reliable viral vectors, plasmid DNA, and other quality-controlled starting materials that support clinical manufacturing and reproducible therapeutic development.

How are CROs and CMOs creating growth opportunities in the gene therapy starting materials market?

CROs and CMOs are the fastest-growing end-use segment as developers outsource complex research, process development, and manufacturing activities to access specialized expertise, scalable infrastructure, and flexible support without major facility investments.

Why does North America lead the gene therapy starting materials market?

North America held 51.12% of market share, supported by advanced biotechnology infrastructure, strong gene therapy research investment, and established manufacturing capabilities emphasizing material quality and regulatory compliance.

What is driving the rapid growth of gene therapy starting materials in Asia Pacific?

Asia Pacific is expected to grow fastest as biotechnology research, domestic biomanufacturing, and clinical development expand, increasing demand for high-quality biological materials for advanced therapies.

Which organizations are considered leaders in the gene therapy starting materials landscape?

Leading players in the gene therapy starting materials market include Thermo Fisher Scientific (USA), Merck (Germany), Lonza (Switzerland), Fujifilm Diosynth (Japan), Sartorius (Germany), Cytiva (USA), Aldevron (USA), AGC Biologics (Japan), WuXi Biologics (China), Takara Bio (Japan).